Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Suspended × talazoparib × Clear all

Phase

Status

Completed 16 Recruiting 7 Withdrawn 3 Terminated 2 Active not recruiting 2 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration Resistant Prostate Cancer (mCRPC) 1

Interventions

Specimen Handling 14 Cyclophosphamide 8 Magnetic Resonance Spectroscopy 7 Biopsy 7 fludarabine 3 X-Rays 3 Paclitaxel 3 Etoposide 3 Carboplatin 3 venetoclax 2 prednylidene 2 fludarabine phosphate 2 durvalumab 2 deltacortene 2 aldesleukin 2 Vincristine 2 Protein Subunit Vaccines 2 Prednisone 2 Nivolumab 2 Leukapheresis 2 Lenalidomide 2 Ipilimumab 2 Interleukin-2 2 E 7107 2 Doxorubicin 2 Cisplatin 2 CTLA-4 Antigen 2 Bevacizumab 2 Antibodies, Monoclonal 2 Actinium 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05425862 2023-12-11

REPAIR

Peter MacCallum Cancer Centre, Australia

Phase 1 Suspended

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡